Login to Your Account



Aduro phase II halted for OS benefit in immunotherapy candidates

By Marie Powers
Staff Writer

Tuesday, January 14, 2014
in_the_clinic.jpg

SAN FRANCISCO ­– Privately held Aduro Biotech Inc. reported that the Phase II trial of cancer immunotherapy candidates, CRS-207 and Gvax Pancreas, used in combination in metastatic pancreatic cancer was halted early on the recommendation of the data safety monitoring board and approval by the FDA after the study met the primary efficacy endpoint at a pre-planned interim analysis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription